An interventional study of Lactase in Prematurity, sponsored by Aristotle University Of Thessaloniki. Completed at 1 site in Greece. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Aristotle University Of Thessaloniki · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Premature Birth with a site in Greece — 7 open to participants now, 8 under way, none of them phase 3. Premature Birth · Greece.
Among the 16 studies in Premature Birth with a site in Greece, this one is the 7th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2025, is one of 9 with no phase, and was the 15th registered.
2,556 studies on the registry are indexed under Premature Birth; 503 are open to participants now.
Browse Premature Birth studies →7 of the 16 studies in Premature Birth with a site in Greece are open now. Recruiting first, the newest first:
Aristotle University Of Thessaloniki · Sites in Greece
Ages 24 wk–29 wk
University of West Attica · Sites in Greece
Ages 28 wk–37 wk
Leiden University Medical Center · Sites in Greece, Austria, Belgium and 16 more countries
Ages up to 32 wk
National and Kapodistrian University of Athens · Sites in Greece
Ages 1 days–3 wk
National and Kapodistrian University of Athens · Sites in Greece, France, Switzerland
Ages 1 days–3 wk
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 317 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 225 (71%) stop at 75 or younger; 242 take children under 18; 104 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Median enrollment 100 across the 13 interventional studies, 6,489 across the 3 observational. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 16 have an industry lead sponsor. The 10 most frequent:
Aristotle University Of Thessaloniki is the lead sponsor of 282 studies on the registry; 55 are open to participants now.
Aristotle University Of Thessaloniki has 2 studies filed under Premature Birth — fewer than ten, so there is no comparison to draw.
3 of the studies in Premature Birth with a site in Greece that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07652684Aristotle University Of ThessalonikiEnteral Lipid Supplementation and Bronchoplumonary Dysplasia of Premature Infants | 2026-11-30 |
| NCT05675397National and Kapodistrian University of AthensPreterm Donor Human Milk Supplementation of Mother's Own Milk in VLBW Infants | 2026-12 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Premature Birth with a site in Greece, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Lactose, a disaccharide that includes the monosaccharides glucose and galactose, is the main carbohydrate found exclusively in mammalian milk. Lactase is found in the intestinal mucosa and is located at the ends of the villi, while it is a factor of maximum clinical importance in milk tolerance and in the occurrence of diarrheal disease. Developmental lactase deficiency is defined as the relative lactase deficiency observed in premature newborns less than 34 weeks of gestation. In the immature gastrointestinal tract, lactase and other disaccharidas are deficient until at least 34 weeks of gestation. One study in premature babies reported a benefit from the use of lactase-supplemented or lactose-reduced formulas, while the use of lactose-containing formulas and human milk did not appear to have short- or long-term harmful effects on infants and infants. Up to 20% of dietary lactose can reach the colon in newborns and young infants.
Due to the inadequate functional development of lactase, premature infants may not digest and absorb the main source of carbohydrate energy, lactose. The high osmotic load associated with indigestible lactose is one of the many possible causes of diarrhea and food intolerance in premature babies. As a result of diarrhea stools and small bowel damage, the already low functional activity of lactase will be further reduced affecting weight gain, while it takes up to 2 weeks for lactase activity to be restored.
Carlson et al showed that the addition of lactase to premature formula reduces the amount of lactose by 70%, with a negligible effect on osmolarity. Previous studies have found that premature infants fed a reduced lactose formula had a better weight gain rate than those who took 100% lactose formula. In two of these studies, weight gain improved despite eating fewer calories.
In the present study we intend to test whether the use of lactase to hydrolysis lactose in premature milk would result in better weight gain and improved dietary tolerance by taking the same calorie intake. This is a prospective, randomized controlled trial with caregivers and investigators responsible for outcome analysis and interpretation masked to treatment allocation to evaluate feeding tolerance and weight gain in preterm infants receiving either (1) human milk or preterm formula supplemented with lactase (intervention group) or (2) human milk or preterm formula without lactase supplementation (non-intervention group).
The study will be carried out at the Second Neonatal Clinic and Neonatal Intensive Care Unit of the Aristotle University of Thessaloniki, in premature newborns (gestational age [GA] 28-34 weeks) who will be hospitalized in the Neonatal Intensive Care Unit.
The study will enroll newborns (1) with a gestational duration of 28 to 34 weeks, (2) who receive ≥75% of their energy needs intestinally, (3) with the absence of severe congenital malformations or gastrointestinal diseases, including necrotizing enterocolitis (NEC) (4) without taking postnatal steroids or diuretics at the time of eligibility assessment. Small, suitable and large for newborns of gestational age will be eligible for the study.
Exclusion criteria will be neonates whose guardians refuse to participate in the study, neonates with congenital malformations or gastrointestinal diseases, and neonates receiving postnatal steroids or diuretics.
The participation of newborns in the study will take place after written consent of the parents after information.
Lactose, a disaccharide that includes the monosaccharides glucose and galactose, is the main carbohydrate found exclusively in mammalian milk. The absorption of lactose requires lactase activity to break the bond that binds the 2 monosaccharides. Lactase is found in the intestinal mucosa and is located at the ends of the villi, while it is a factor of maximum clinical importance in milk tolerance and in the occurrence of diarrheal disease.
Milk intolerance can be attributed to either lactose or protein content. Lactose intolerance may occur in infants and young children with acute diarrhoea, although its clinical significance is limited. Lactose intolerance symptoms are relatively common among older children and adolescents. However, associated intestinal damage is rarely observed. Lactose tolerance is a separate entity from cow's milk protein allergy, which is of immune etiology and can cause varying degrees of intestinal mucosal injury. Cow's milk protein intolerance is reported in 2% to 5% of infants within the first 1 to 3 months of life, usually subsides by the age of 1 year and is not the subject of this statement.
In more specific cases, the hydrogen breath test is the least invasive and most helpful test for diagnosing lactose malabsorption. The test is performed by administering a standardized amount of lactose (2 g/kg, up to a maximum of 25 g, equivalent to the amount of lactose in 2 glasses of milk) after fasting overnight and then measuring the amount of hydrogen in the exhaled air for a period of 2 to 3 hours. An increase (20 ppm) in hydrogen after about 60 minutes is indicative of lactose malabsorption. Factors that may produce false negative or false positive results include conditions affecting the intestinal flora (e.g., recent use of antimicrobial agents), lack of hydrogen-producing bacteria (10%-15% of the population), ingestion of a high-fiber diet before testing, bacterial overgrowth of the small intestine, or intestinal motility disorders.
In newborns and infants with diarrhea in whom lactose (or other carbohydrate) intolerance is suspected, the stool can be checked for carbohydrate malabsorption by testing the pH of the stool, which is reduced by carbohydrate malabsorption as a result of the formation of volatile fatty acids. It is noted that the pH of the stool is lower in infants compared to older children and adolescents due to the normal overload of lactose in their diet; which in turn helps to promote the growth of Lactobacillus species in the large intestine. Reducing substances can also be detected in the stool, such as reducing sugars that include lactose, glucose, fructose and galactose, but not sucrose. Because some patients may only absorb enough carbohydrates, such as lactose, to lower the pH of the stool but not increase the excretion of carbohydrates in the stool, the pH test is a more sensitive test for carbohydrate malabsorption.
Developmental lactase deficiency is defined as the relative lactase deficiency observed in premature newborns less than 34 weeks of gestation. In the immature gastrointestinal tract, lactase and other disaccharidesas are deficient until at least 34 weeks of gestation. One study in premature babies reported a benefit from the use of lactase-supplemented foods or lactose-reduced preparations. While the use of lactose-containing preparations and human milk does not appear to have short- or long-term harmful effects on newborns and infants. Up to 20% of dietary lactose can reach the colon in newborns and young infants. The metabolism of lactose by colon microbes lowers the pH of the stool, which has a beneficial effect, favoring certain organisms (e.g. Bifidobacterium and Lactobacillus species) instead of potential pathogens (Proteus, Escherichia coli and Klebsiella species) in young infants.
Lactase is detected for the first time in the fetus from the 10th week of gestation. At 28 to 34 weeks, lactase activity is only \~30% of that found at the end of pregnancy. At 35 to 38 weeks, it reaches 70% of the activity of the end months. Due to the inadequate functional development of lactase, premature infants may not digest and absorb the main source of carbohydrate energy, lactose. The high osmotic load associated with indigestible lactose is one of the many possible causes of diarrhea and food intolerance in premature babies. As a result of diarrhea stools and small bowel damage, the already low functional activity of lactase will be further reduced affecting weight gain, while it takes up to 2 weeks for lactase activity to be restored.
Lactose intolerance is often treated with soy proteins, protein hydrolysis products, low-lactose, or lactose-free formulas. However, these types do not meet the nutritional requirements for the development and development of premature newborns, which need human milk with a human milk booster or premature milk. Ideally, premature babies with lactose intolerance should take these hydrolyzed lactose foods. Carlson et al showed that the addition of lactase to premature formula reduces the amount of lactose by 70% after a 2-hour incubation period at room temperature, with negligible effect on osmolarity. Previous studies have found that premature infants fed a reduced lactose formula had a better weight gain rate than those who took 100% lactose formula. In two of these studies, weight gain improved despite eating fewer calories.
In the present study we intend to test whether the use of lactase to hydrolysis lactose in premature milk would result in better weight gain and improved dietary tolerance by taking the same calorie intake.
METHOD Study Population A prospective, randomized controlled trial with caregivers and investigators responsible for outcome analysis and interpretation masked to treatment allocation will be conducted to evaluate feeding tolerance and weight gain in preterm infants receiving either (1) human milk or preterm formula supplemented with lactase (intervention group) or (2) human milk or preterm formula without lactase supplementation (non-intervention group).
Study Day 1 will be the day on which intestinal feeding will provide ≥75% of the daily intake of caloric needs. The study will be terminated when the newborn reaches 36 weeks or is discharged from the unit, whichever comes first.
Inclusion criteria The study will enrol newborns (1) with a gestational duration of 28 to 34 weeks, (2) who receive ≥75% of their energy needs intestinally, (3) with the absence of severe congenital malformations or gastrointestinal diseases, including necrotizing enterocolitis (NEC) (4) without taking postnatal steroids or diuretics at the time of eligibility assessment. Small, suitable and large for newborns of gestational age will be eligible for the study.
Exclusion criteria Exclusion criteria will be neonates whose guardians refuse to participate in the study, neonates with congenital malformations or gastrointestinal diseases, and neonates receiving postnatal steroids or diuretics.
Feeding newborns The feeding of the newborns of the study will be in accordance with the usual practices of the clinic, i.e. the first choice will be breast milk, the second the human milk of the donor from the milk bank and the third choice the formula of premature newborns. Breast milk fortifiers will be added to breast milk according to the usual clinic practices, i.e. when the volume of milk administered exceeds 25 ml per meal.
Human milk is given an estimated caloric value of 68 kcal/100 mL, while premature formula is given 81 kcal/100 mL.
Randomization Guardians of newborns who meet the criteria for inclusion in the study will be approached to be informed about participation in the study. Newborns whose guardians consent to participate will be included in the study.
Newborns, after enrolment in the study, will be randomized to either the lactase group or the control group. The results of randomization will not be known to the principal investigator until after the study is completed.
Intervention Newborns in the lactase group will receive milk fortified with 2 drops of lactase/kg of body weight per meal. The enrichment of the milk with lactase drops will be carried out by the nurse on duty without it being known by the principal investigator to which group (lactase group or control group) each newborn belongs. Only a secondary researcher and the shift nurse will have access to neonatal randomization information.
The lactase drops that will be used in the study will be Delictase®. The supply of Delictase® lactase preparations will be carried out by Prime Biosciences, every 2 months at the study site.
Recording of results For all newborns in the study, perinatal and neonatal data will be recorded on computers anonymously by the researchers. Somatometric data (body weight, head circumference, body length) will be recorded at birth and per week until the completion of the study. Biochemical markers of homeostasis (protein, albumin, sodium, and potassium) will also be recorded according to the usual practices of neonatal hospitalization in the NICU. Caloric intake and type of food will be recorded daily The main outcome variable will be daily weight-gain velocity from study entry to study completion, calculated for each infant as the difference between body weight at study completion and body weight on study day one divided by the number of study days.
Secondary outcomes will include head circumference and length gain velocities. Other prespecified outcomes will include abdominal distension, emesis, bowel-movement frequency, and serum total protein, albumin, sodium, and potassium concentrations. Gastric residual volume and stool reducing substances were prespecified feeding-tolerance measures but were not incorporated into prospective data collection and therefore were not available for analysis. Feeding-tolerance outcomes will include abdominal distension, emesis, and bowel-movement frequency. Abdominal distension will be recorded as the occurrence of clinically apparent abdominal distension at any time during the study period. For emesis, weekly incidence will be defined as the proportion of infants experiencing at least one day with >2 episodes within 24 hours during the respective study week. Bowel-movement frequency will be recorded as the number of bowel movements per day.
Serum protein, albumin, sodium, and potassium concentrations will be obtained according to routine clinical practice and will be also recorded. Finally, any withdrawal from the study due to feeding intolerance or NEC will be recorded.
Statistical analysis According to previous studies, the main outcome of the study (weight gain, g/day) was used as the basis for calculating the sample size. A total of 100 newborns (50 newborns per group) allows the detection of a 33% increase in mean weight gain per day in the treatment group, with a strength of 0.80. The differences between the groups are considered statistically significant at the level of P \<.05.
Neonatal characteristics of the lactase and control group will be compared with the t-test in terms of continuous variables (caloric intake, weight gain, length, head circumference, gastric residual volume, daily number of vomiting episodes, daily stool count, and serum albumin, total protein, sodium, and potassium concentrations) or the Mann-Whitney test for variables with abnormal dispersion. The Pearson X2 or Fisher exact test will be used to compare the categorical variables (proportion of neonates in each group who developed food intolerance, had at least one episode of vomiting during the study, withdrew from the study due to medical condition or parental request, or experienced NEC) between the two groups.
Regression analysis will be used to check the correlation of weight gain with lactase administration or not, stratified for perinatal and neonatal factors with statistical significance.
Duration of the study Recruitment is expected to begin in August 2025 and be completed within 24 months.
The criteria were revised on the registry on Oct 8, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Newborns in the lactase group will receive milk fortified with 2 drops of lactase/kg of body weight per meal. The enrichment of the milk with lactase drops will be carried out by the nurse on duty without it being known by the principal investigator to which group (lactase group or control group) each newborn belongs. Only a secondary researcher and the shift nurse will have access to neonatal randomization information. The lactase drops that wiil be used in the study will be Delictase, an exogenous source of the lactase enzyme, which contains 126 Acid Lactase Units (ALU) of lactase per drop.The supply of Delictase® lactase preparations will be carried out by Prime Biosciences, every 2 months at the study site.
Dietary Supplement: Lactase
The feeding of the newborns of the study will be in accordance with the usual practices of the clinic, i.e. the first choice will be breast milk, the second the human milk of the donor from the milk bank and the third choice the formula of premature newborns. Breast milk boosters will be added to breast milk according to the usual clinic practices, i.e. when the volume of milk administered exceeds 25 ml per meal. Human milk is given an estimated caloric value of 68 kcal/100 mL, while premature formula is given 81 kcal/100 mL.
The lactase drops that will be used in the study will be Delictase®, an exogenous source of the lactase enzyme, which contains 126 Acid Lactase Units (ALU) of lactase per drop. The supply of Delictase® lactase preparations will be carried out by Prime Biosciences, every 2 months at the study site.
Weight-gain velocity
The primary outcome will be mean daily weight-gain velocity from study entry to study completion, calculated for each infant as the difference between body weight at study completion and body weight on study day one divided by the number of study days. Unit of Measure: g/d
Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
Head circumference gain velocity
Head circumference gain velocity from study entry to study completion will be calculated for each infant as the difference between head circumference at study completion and head circumference on study day one divided by the number of study weeks. Unit of Measure: cm/week
Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
Length gain velocity
Length gain velocity from study entry to study completion will be calculated for each infant as the difference between body length at study completion and body length on study day one divided by the number of study weeks. Unit of Measure: cm/week
Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
Occurrence of abdominal distension
Occurrence of clinically apparent abdominal distension at any time during the study period. Unit of Measure: Participants
Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
Weekly incidence of emesis
Weekly incidence of emesis will be defined as the proportion of infants experiencing at least one day with more than 2 episodes of emesis within 24 hours during the respective study week. Unit of Measure: Percentage of participants
Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
Bowel-movement frequency
Bowel-movement frequency will be recorded as the number of bowel movements per day. Unit of Measure: bowel movements/day
Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
Serum total protein concentration
Serum total protein concentration obtained according to routine clinical practice during the study period. Unit of Measure: g/dL
Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
Serum albumin concentration
Serum albumin concentration obtained according to routine clinical practice during the study period.Unit of Measure: g/dL
Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
Serum sodium concentration
Serum sodium concentration obtained according to routine clinical practice during the study period. Unit of Measure: mmol/L
Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
Serum potassium concentration
Serum potassium concentration obtained according to routine clinical practice during the study period. Unit of Measure: mmol/L
Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
Gastric residual volume
Gastric residual volume was a prespecified feeding-tolerance measure but was not incorporated into prospective data collection and therefore was not available for analysis. Unit of Measure: mL
Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
Stool reducing substances
Stool reducing substances were a prespecified feeding-tolerance measure but were not incorporated into prospective data collection and therefore were not available for analysis. Unit of Measure: Not applicable
Time frame: From study entry until 36 weeks' PMA or discharge, whichever occurred first.
Plan to share: Yes — Deidentified data can be available upon reasonable request.
Ran from Aug 2025 to primary completion in Aug 2026, 12 months.
Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's 12 months is below that.
Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Aug 2027 → Aug 2026 and completion Aug 2027 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lactase
Aristotle University Of Thessaloniki →